Should you take vitamin D and K2 together?
The combination of vitamin D and K2 is one of the most frequently recommended pairings in the supplement market. The logic behind it sounds compelling: vitamin D increases calcium absorption, K2 ensures that calcium ends up in bone rather than arteries, and taking them together is therefore safer and more effective than taking either alone. This narrative is widely repeated across health content, supplement labelling, and clinical nutrition writing.
The biological rationale is coherent. Whether it translates into demonstrated clinical benefit from the combination specifically, beyond what each nutrient does individually, is a separate question, and one the evidence base has not yet answered clearly. Understanding that distinction is the basis for a genuinely useful answer to whether you should take them together.
What each nutrient does
Vitamin D is a fat-soluble prohormone that plays a central role in calcium and phosphate metabolism. Its most established function is enabling intestinal calcium absorption, without adequate vitamin D, absorbed dietary calcium drops substantially, and the body draws on bone stores to maintain serum calcium levels. Deficiency is associated with rickets in children and osteomalacia and increased fracture risk in adults. Evidence for vitamin D supplementation is strongest in people with deficient or insufficient status, and in older adults at risk of falls and fractures.
Vitamin K2 (menaquinone) is a fat-soluble vitamin involved in the activation of two proteins with direct relevance to calcium handling: osteocalcin, which is required for calcium incorporation into bone matrix, and matrix Gla protein (MGP), which inhibits calcium deposition in soft tissue including arterial walls. Both proteins require carboxylation by vitamin K-dependent enzymes to become biologically active. Without sufficient vitamin K2, these proteins remain in their inactive, undercarboxylated forms.
The most studied supplemental form is MK-7 (menaquinone-7), which has a longer half-life than MK-4 and reaches higher and more stable circulating concentrations at typical supplemental doses.
Where the combination claim comes from
The mechanistic case for combining vitamin D and K2 rests on a plausible concern: vitamin D increases intestinal calcium absorption, and if that additional calcium is not directed into bone efficiently, or if soft tissue calcification is not adequately suppressed, the net result could theoretically include increased arterial calcium deposition. Vitamin K2, by activating MGP, is proposed to prevent this.
This concern has a basis in the evidence. Undercarboxylated MGP is associated with arterial calcification in observational studies. Low vitamin K status has been linked to higher cardiovascular risk in epidemiological data. And the proteins that K2 activates are genuinely involved in the biology being described. The mechanistic chain is real.
The leap is from a coherent mechanism to a demonstrated clinical need for the combination. The concern that vitamin D supplementation at typical doses meaningfully increases arterial calcification risk in people with adequate K2 status has not been established in clinical trials. And the hypothesis that adding K2 to vitamin D supplementation produces better clinical outcomes than vitamin D alone, for bone, for cardiovascular endpoints, or for any other outcome, has not been confirmed in adequately powered trials.
What the evidence on K2 alone shows
The strongest evidence for vitamin K2 supplementation in isolation relates to bone outcomes, particularly in postmenopausal women. A meta-analysis by Fang et al. (2012, Food and Chemical Toxicology; 13 RCTs) found that MK-4 supplementation reduced vertebral fracture risk and improved bone mineral density in postmenopausal women. This evidence is suggestive but should be read carefully: the trials were conducted predominantly in Japanese populations, many were small with variable methodological quality, and the meta-analysis has been criticised for heterogeneity across included studies. The MK-4 doses used were high, typically 45 mg daily, a pharmaceutical dose unavailable in standard consumer supplements, which typically provide MK-7 at 100 to 200 mcg. The generalisability of this evidence to Western populations supplementing MK-7 at lower doses is limited.
Evidence for MK-7 at lower doses on bone outcomes is more limited and less consistent. Knapen et al. (2013, Osteoporosis International; RCT, n = 244, postmenopausal women, 180 mcg MK-7 daily for three years) found improvements in bone strength indices and attenuation of age-related bone loss compared to placebo, with no significant fracture data. This is a single trial with surrogate bone outcomes rather than fracture endpoints.
For cardiovascular outcomes, the Rotterdam Study (Geleijnse et al., 2004, Journal of Nutrition; n = 4,807) found that higher dietary menaquinone intake was associated with lower coronary heart disease risk and all-cause mortality. This association is frequently cited in K2 marketing but is an observational finding in a general dietary context, not a trial of K2 supplementation, and observational dietary data of this kind is susceptible to confounding by diet quality and lifestyle. There are no large randomised controlled trials demonstrating that K2 supplementation reduces cardiovascular events. The interventional evidence base for cardiovascular outcomes from K2 supplementation specifically remains very limited.
What the evidence on the combination shows
Direct randomised controlled trial evidence examining the combination of vitamin D and K2 against either nutrient alone, on clinical endpoints such as fractures, arterial calcification, or cardiovascular events, is sparse. To be precise: there are no large, adequately powered RCTs demonstrating that vitamin D and K2 together improves outcomes compared to vitamin D alone on any of these endpoints. This is the central evidential gap in the combination argument.
A small number of trials have examined the combination on surrogate outcomes. Some trials in specific clinical populations, including haemodialysis patients and postmenopausal women, have examined the combination on vascular calcification markers. The results have been mixed and the populations studied are not representative of the generally healthy adult taking supplements preventively.
The most frequently cited mechanistic concern, that vitamin D supplementation without K2 increases cardiovascular risk through arterial calcification, has not been demonstrated in clinical trials. Large vitamin D supplementation trials, including VITAL (Manson et al., 2019, NEJM; n = 25,871), have not reported increased cardiovascular risk with vitamin D supplementation. It should be noted that VITAL was not designed or powered to detect calcification-specific endpoints, so this does not definitively rule out the theoretical concern, but it does mean the clinical urgency of the K2 co-supplementation argument rests on a theoretical risk that has not materialised in large outcome data.
Who has the strongest case for both
The populations where a genuine evidence-informed rationale for both nutrients exists are relatively specific.
Postmenopausal women with low vitamin D status and suboptimal dietary vitamin K intake have evidence supporting both nutrients individually for bone outcomes, and the combination is biologically coherent in this context. Older adults more broadly, where vitamin D deficiency is common and bone loss is clinically significant, represent a similar picture. Individuals with conditions affecting fat absorption, since both vitamins are fat-soluble, may have suboptimal status of both and a reasonable case for supplementing both.
For generally healthy adults with adequate vitamin D status and a diet that includes fermented foods, dairy, and some animal products providing menaquinones, the urgency of the combination is less clear. An important conceptual anchor here is the deficiency distinction: vitamin D's benefits are largely deficiency-driven, and the evidence for supplementation in replete individuals is considerably weaker. Vitamin K2 is not yet established as a nutrient with a well-defined deficiency syndrome in the way vitamin D is, and the threshold at which K2 status becomes functionally limiting in an otherwise healthy adult is not well established. For both nutrients, the case for supplementation is strongest where status is demonstrably low.
Dosing and form considerations
For vitamin D, the evidence-based supplemental dose for most adults in the UK is 400 to 2,000 IU daily depending on baseline status, with higher doses used clinically under guidance. Testing 25-hydroxyvitamin D is the most reliable way to establish whether supplementation is addressing a genuine gap. At high doses, vitamin D can cause hypercalcaemia, elevated serum calcium with symptoms including nausea, fatigue, and kidney complications. This is not a risk at typical supplemental doses but is relevant context for the broader combination argument: the concern about calcium direction is dose-dependent, and at standard doses the clinical significance is uncertain.
For K2, MK-7 at 100 to 200 mcg daily is the most commonly studied dose in supplementation trials and is the most practical form given its longer half-life. Long-term safety data on MK-7 supplementation at these doses is limited, most trials are short to medium duration, and the absence of demonstrated harm should not be equated with confirmed long-term safety.
One practical note: vitamin K2 at supplemental doses can interact with anticoagulant medications including warfarin, which works by antagonising vitamin K activity. Anyone taking warfarin or related anticoagulants should not supplement with K2 without medical guidance. This interaction applies to all vitamin K forms.
What can reasonably be concluded
The mechanistic case for taking vitamin D and K2 together is coherent and grounded in real biology. The proteins that K2 activates are genuinely involved in calcium direction, and the concern that higher calcium absorption without adequate K2 activity could have adverse effects has a mechanistic basis, though the clinical corroboration for this concern in people supplementing at typical doses is limited.
The clinical evidence for the combination specifically, as distinct from the evidence for each nutrient individually, is limited and has not established that co-supplementation produces better outcomes than vitamin D alone in healthy adults. There are no large RCTs demonstrating superiority of the combination. To be explicit: there is no evidence that adding K2 to vitamin D improves fracture risk, cardiovascular outcomes, or mortality compared to vitamin D alone. The theoretical cardiovascular risk of vitamin D without K2 has not materialised in large supplementation trials.
The practical answer is that taking both is a defensible but not evidence-driven choice for people who have good reasons to supplement both individually, particularly older adults, postmenopausal women, or those with low dietary K2 intake and confirmed vitamin D insufficiency. The default should not drift toward the combination unless there is a specific indication for both nutrients. For generally healthy adults with adequate vitamin D levels and a reasonably varied diet, the case for the combination rests on biological plausibility rather than demonstrated clinical benefit.
There is no evidence of harm at typical supplemental doses, and the rationale is not groundless. But the marketing claim that K2 is necessary to make vitamin D supplementation safe, or that the combination is substantially superior to vitamin D alone, goes further than the current evidence supports.
Where evidence is limited or outcomes are uncertain, conclusions should be treated as provisional and subject to revision as the evidence base develops.
Key references
Fang Y et al. (2012). Effect of vitamin K on bone mineral density: a meta-analysis of randomized controlled trials. Food and Chemical Toxicology, 50(6), 1590-1596. doi:10.1016/j.fct.2012.02.055
Knapen MHJ et al. (2013). Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporosis International, 24(9), 2499-2507. doi:10.1007/s00198-013-2325-6
Geleijnse JM et al. (2004). Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease. Journal of Nutrition, 134(11), 3100-3105. doi:10.1093/jn/134.11.3100
Manson JE et al. (2019). Vitamin D supplements and prevention of cancer and cardiovascular disease. NEJM, 380(1), 33-44. doi:10.1056/NEJMoa1809944
For detailed evidence profiles on each nutrient individually, see the Vitamin D entry and Vitamin K2 entry in the Evidentia library.